Migraitan

Sumatriptan, the active ingredient in Migraitan, is a 5‑HT1B/1D receptor agonist presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults and works by reversing the vascular and neurogenic changes that underlie migraine pain.

GNH USA supplies Migraitan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for healthcare providers across multiple regions, including Europe, Asia and Africa.

Sumatriptan belongs to the triptan class and is used for acute migraine management.

- Migraine attack: aborts an ongoing migraine episode, relieving headache and associated symptoms. - Migraine with aura: provides rapid relief of headache and visual disturbances when taken at onset. - Cluster headache: can be used to treat acute attacks of cluster headache in adults.

Common Side Effects: - Chest discomfort: mild pressure or tightness in the chest. - Tingling or numbness: sensation of pins and needles, often in the face or extremities. - Nausea: upset stomach or urge to vomit. - Dizziness: feeling light‑headed or unsteady. - Dry mouth: reduced salivation. - Fatigue: unusual tiredness or lack of energy.

Serious or Rare Side Effects: - Coronary vasospasm: sudden narrowing of coronary arteries that can cause chest pain. - Serotonin syndrome: potentially life‑threatening condition when combined with other serotonergic agents. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Hypertension: significant increase in blood pressure. - Myocardial infarction: heart attack in susceptible individuals. - Severe skin reactions: such as Stevens‑Johnson syndrome.

Before using Sumatriptan, consider the following precautions: - Cardiovascular assessment: avoid in patients with uncontrolled coronary artery disease or recent myocardial infarction. - Serotonergic drugs: caution when combined with SSRIs, SNRIs, or MAO inhibitors due to risk of serotonin syndrome. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Renal or hepatic impairment: dose adjustment may be required; monitor liver and kidney function. - Age restrictions: not recommended for children under 12 years of age. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Sumatriptan may interact with several drug classes. Review the following interactions before prescribing.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can precipitate severe hypertension. - Ergotamine derivatives: combined vasoconstrictive effects increase risk of coronary spasm. - Other triptans: additive vasoconstriction may lead to cardiovascular events. - Monoamine oxidase inhibitors: heightened risk of serotonin syndrome. - Certain antihypertensives: may potentiate blood pressure changes.

Moderate Interactions (Monitor Closely): - SSRIs and SNRIs: monitor for signs of serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole): may increase sumatriptan plasma levels. - Antihistamines: can enhance dizziness or sedation. - Oral contraceptives: may affect metabolism, requiring observation.